metformin has been researched along with Elevated Cholesterol in 24 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study included two age-, weight-, lipid-, and prolactin level-matched groups of premenopausal women with hypecholesterolemia and a history of hyperprolactinemia: patients treated with bromocriptine (5." | 9.20 | The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia. ( Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W, 2015) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 9.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 9.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "The study included two age-, weight-, lipid-, and prolactin level-matched groups of premenopausal women with hypecholesterolemia and a history of hyperprolactinemia: patients treated with bromocriptine (5." | 5.20 | The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia. ( Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W, 2015) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 5.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 5.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "Diabetes mellitus type 2 with dyslipidemia is a common disease." | 2.77 | Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. ( Dabaghian, FH; Hajiaghaee, R; Huseini, HF; Kianbakht, S, 2012) |
| "Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer." | 2.52 | Obesity and cancer: mechanistic insights from transdisciplinary studies. ( Allott, EH; Hursting, SD, 2015) |
| "Metabolic syndrome is prevalent in older adults and increases the risk of cardiovascular disease." | 2.45 | Metabolic risks in older adults receiving second-generation antipsychotic medication. ( Brooks, JO; Chang, HS; Krasnykh, O, 2009) |
| "Obesity is an increasingly prevalent problem with many associated health risks." | 2.42 | Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. ( Ghali, P; Lindor, KD, 2004) |
| "Inflamed atherosclerotic plaques can be visualized by noninvasive positron emission and computed tomographic imaging with (18)F-fluorodeoxyglucose, a glucose analog, but the underlying mechanisms are poorly understood." | 1.43 | Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice. ( De Vivo, DC; Gautier, EL; Giorgetti-Peraldi, S; Guinamard, R; Ivanov, S; Sarrazy, V; Thorp, EB; Viaud, M; Westerterp, M; Yvan-Charvet, L, 2016) |
| "Her treatment was metformin 850 mg every 12 hours and glimepiride 4 mg every 24 hours." | 1.40 | How to prevent and treat pharmacological hypoglycemias. ( Mezquita Raya, P; Reyes García, R, 2014) |
| "Metformin was selected as the test compound, because it has been shown to decrease aortic and liver lipid accumulation in cholesterol fed rabbits, while only slightly affecting plasma cholesterol levels." | 1.26 | Turnover and aortic uptake of very low density lipoproteins (VLDL) from hypercholesteremic rabbits as a model for testing antiatherosclerotic compounds. ( Catapano, A; Ghiselli, GC; Rodriguez, J; Sirtori, CR, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (29.17) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Goldenberg, R | 2 |
| Bell, A | 2 |
| Cheng, W | 2 |
| Paron, E | 1 |
| Fils-Aimé, N | 2 |
| Burrows, M | 2 |
| Blavignac, J | 2 |
| Barakat, M | 2 |
| Parron, E | 1 |
| Carris, NW | 1 |
| Tsalatsanis, A | 1 |
| Tipparaju, SM | 1 |
| Cheng, F | 1 |
| Magness, RR | 1 |
| Kumar, A | 1 |
| Reyes García, R | 1 |
| Mezquita Raya, P | 1 |
| Liu, Y | 1 |
| Huang, C | 1 |
| Ceng, C | 1 |
| Zhan, H | 1 |
| Zheng, D | 1 |
| Han, W | 1 |
| Krysiak, R | 1 |
| Gilowski, W | 1 |
| Szkrobka, W | 1 |
| Okopien, B | 1 |
| Allott, EH | 1 |
| Hursting, SD | 1 |
| Sarrazy, V | 1 |
| Viaud, M | 1 |
| Westerterp, M | 1 |
| Ivanov, S | 1 |
| Giorgetti-Peraldi, S | 1 |
| Guinamard, R | 1 |
| Gautier, EL | 1 |
| Thorp, EB | 1 |
| De Vivo, DC | 1 |
| Yvan-Charvet, L | 1 |
| Brooks, JO | 1 |
| Chang, HS | 1 |
| Krasnykh, O | 1 |
| Simons, WR | 1 |
| Hagan, MA | 1 |
| Oner, G | 1 |
| Muderris, II | 1 |
| Huseini, HF | 1 |
| Kianbakht, S | 1 |
| Hajiaghaee, R | 1 |
| Dabaghian, FH | 1 |
| Vignini, A | 1 |
| Giulietti, A | 1 |
| Nanetti, L | 1 |
| Raffaelli, F | 1 |
| Giusti, L | 1 |
| Mazzanti, L | 1 |
| Provinciali, L | 1 |
| Serrano Rios, M | 1 |
| Ascaso Gimilio, JF | 1 |
| Blázquez Fernández, E | 1 |
| Cabezas Cerraro, J | 1 |
| Carmena Rodríguez, R | 1 |
| Escobar Jiménez, F | 1 |
| Fernández-Real, JM | 1 |
| Gabriel Sánchez, R | 1 |
| Gomis de Barberá, R | 1 |
| Grande Aragón, C | 1 |
| Herrera Pomba, JL | 1 |
| Pallardo Sánchez, LF | 1 |
| Potau Vilalta, N | 1 |
| Ricart Engel, W | 1 |
| Rovira Loscos, A | 1 |
| Zorzano Olarte, A | 1 |
| Ghali, P | 1 |
| Lindor, KD | 1 |
| Baptista, T | 1 |
| Martínez, J | 1 |
| Lacruz, A | 1 |
| Rangel, N | 1 |
| Beaulieu, S | 1 |
| Serrano, A | 1 |
| Arapé, Y | 1 |
| Martinez, M | 1 |
| de Mendoza, S | 1 |
| Teneud, L | 1 |
| Hernández, L | 1 |
| Tremoli, E | 1 |
| Ghiselli, G | 1 |
| Maderna, P | 1 |
| Colli, S | 1 |
| Sirtori, CR | 4 |
| Giacchi, M | 1 |
| Vatti, R | 1 |
| Tanser, P | 1 |
| Archer, S | 1 |
| Feldman, R | 1 |
| Rodriguez, J | 3 |
| Catapano, A | 2 |
| Ghiselli, GC | 2 |
| Innocenti, AL | 1 |
| Innocenti, L | 1 |
| Grigolato, PG | 1 |
| Crepaldi, G | 1 |
| Fellin, R | 1 |
| Briani, G | 1 |
| Baggio, G | 1 |
| Baiocchi, MR | 1 |
| Marquié, G | 1 |
| Agid, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance[NCT03575000] | Phase 4 | 20 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for metformin and Elevated Cholesterol
| Article | Year |
|---|---|
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Metabolic risks in older adults receiving second-generation antipsychotic medication.
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Antipsychotic Agents; Cardiovascular Diseas | 2009 |
Alzheimer's disease and diabetes: new insights and unifying therapies.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Diabetes Mell | 2013 |
Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.
Topics: Antihypertensive Agents; Comorbidity; Diabetes Mellitus; Glucosidases; Humans; Hypercholesterolemia; | 2004 |
4 trials available for metformin and Elevated Cholesterol
| Article | Year |
|---|---|
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; D | 2015 |
Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adolescent; Adult; Anticholesteremic Agents; Antioxidants; Body Mass Index; Female; | 2011 |
Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial.
Topics: Adult; Aloe; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gels; Glyburide; Humans; Hyperc | 2012 |
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Typ | 2006 |
16 other studies available for metformin and Elevated Cholesterol
| Article | Year |
|---|---|
Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Chlorthalidone; Col | 2020 |
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry,
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Cardiovascular Dise | 2020 |
Metformin's impact on statin-associated muscle symptoms: An analysis of ACCORD study data and research materials from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center.
Topics: Aged; Biological Specimen Banks; Diabetes Mellitus, Type 2; Electronic Health Records; Female; Follo | 2018 |
How to prevent and treat pharmacological hypoglycemias.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hyperc | 2014 |
Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Drug Evaluation, Preclinical; H | 2014 |
Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Bone Marrow Transplantation; Cell Division; Cytokine Re | 2016 |
An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
Topics: Adult; Aged; Allylamine; Cardiovascular Diseases; Cholesterol, LDL; Colesevelam Hydrochloride; Cost- | 2010 |
[Insulin resistance and its involvement in multiple risk factors associated with type 2 diabetes mellitus].
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypercholesterolemia; Hyperli | 2002 |
Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits.
Topics: Animals; Blood Platelet Disorders; Blood Platelets; Cholesterol, Dietary; Collagen; Hypercholesterol | 1982 |
[Inhibitory effect of metformin on the development of cholesterol atherosclerosis in the rabbit. Observations on the coronary vessels].
Topics: Animals; Arteriosclerosis; Cholesterol; Coronary Vessels; Diet, Atherogenic; Hypercholesterolemia; M | 1981 |
Case 2. Recurrence of myocardial infarction.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Drug Therapy, Combination; | 2000 |
Turnover and aortic uptake of very low density lipoproteins (VLDL) from hypercholesteremic rabbits as a model for testing antiatherosclerotic compounds.
Topics: Animals; Aorta; Apoproteins; Arteriosclerosis; Cholesterol; Disease Models, Animal; Hypercholesterol | 1976 |
Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits.
Topics: Animals; Aorta; Apolipoproteins; Blood Glucose; Cholesterol; Fatty Acids; Hypercholesterolemia; Lipo | 1977 |
Turnover and aortic uptake of very low density lipoproteins (VLDL) from hypercholesteremic rabbits: effect of metformin.
Topics: Animals; Aorta; Apolipoproteins; Cholesterol; Cholesterol Esters; Hypercholesterolemia; Lipoproteins | 1977 |
[Treatment of hyperlipoproteinemias (author's transl)].
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Cholestyramine Resin; Clofibrate; Dextrothyroxin | 1974 |
[Prevention with dimethylbiguanide of thyroid changes caused by an atherogenic diet in rabbits].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Diet, Atherogenic; Hypercholesterolemia; Hypoth | 1972 |